Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment ...
Then $75 per month. Complete digital access to quality FT journalism on any device. Cancel or change your plan anytime during your trial. Complete digital access to quality FT journalism with expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback